Thursday 16 October, 2025
Introduction: Inflammatory bowel disease (IBD) comprises two distinct yet closely related disorders: Crohn’s disease and ulcerative colitis. Infliximab, a monoclonal…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Physiologically-Based Pharmacokinetic Modelling of Niraparib in Special Populations
Thursday 16 October, 2025
Objectives: Poly ADP-ribose polymerase inhibitors (PARPi) have demonstrated significant efficacy in gynecological oncology. However, their clinical application is frequently limited…
Read moreEvaluating Metformin Exposure through PBPK Modeling: A Comparative Study between Cancer Patients and Healthy Subjects
Thursday 16 October, 2025
Introduction: Meta-analysis of clinical studies has demonstrated that pharmacokinetics of drugs may be altered in cancer patients compared to healthy…
Read morePhysiologically Based Pharmacokinetic (PBPK) Modeling of Atorvastatin and Its Three Relevant Metabolites to predict CYP3A4 and OATP1B1-mediated Drug-Drug-Gene Interactions
Thursday 16 October, 2025
Introduction: Atorvastatin, a widely prescribed hydroxymethylglutaryl-CoA(HMG-CoA) reductase inhibitor for hyperlipidemia, exhibits potent lipid-lowering efficacy but is associated with dose-dependent muscular…
Read morePhysiologically based pharmacokinetic modeling to predict the pharmacokinetics of metformin, saxagliptin and dapagliflozin in normal and special patient populations
Thursday 16 October, 2025
Introduction/Objectives Although metformin remains the first line of diabetes treatment as monotherapy, there may be the need for combination with…
Read morePHYSIOLOGICALLY BASED BIOPHARMACEUTICS MODELING FOR VIRTUAL BIOEQUIVALENCE ASSESSMENT OF METFORMIN IMMEDIATE AND EXTENDED-RELEASE FORMULATIONS
Thursday 16 October, 2025
PHYSIOLOGICALLY BASED BIOPHARMACEUTICS MODELING FOR VIRTUAL BIOEQUIVALENCE ASSESSMENT OF METFORMIN IMMEDIATE AND EXTENDED-RELEASE FORMULATIONS Frederico S. Martins1, Tarang Vora1, Grace…
Read moreA meta-model-based workflow for massive efficiency gains when applying global sensitivity analysis to PBPK models
Thursday 16 October, 2025
Introduction: Sensitivity Analysis (SA) describes a class of methods for studying the relationships between the inputs and outputs of a…
Read morePBPK Modeling to Recommend Nevirapine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction, Drug Interactions, and Ethnic Variability
Thursday 16 October, 2025
Objectives: Highly active antiretroviral therapy (ART) has significantly reduced HIV-related mortality and morbidity. However, tuberculosis (TB) remains a leading cause…
Read moreAcross species translation of a novel liver-targeted GalNAc conjugated siRNA using a minimal PBPK/PD approach
Thursday 16 October, 2025
Introduction: Small interfering ribonucleic acid (siRNA) is an emerging class of targeted therapies that aims to regulate the expression of…
Read moreEvaluating model-based extrapolation for generic long-acting injectable (LAI) products: from single- to multiple-dose studies
Thursday 16 October, 2025
Introduction Long-acting injectable (LAI) products are designed for prolonged drug release, offering benefits such as improved compliance and patient outcomes….
Read more